Coming Off an Antidepressant Without the Crash: Withdrawal, Relapse, and How Tapers Really Work

You missed a dose. Now you feel dizzy, sick, wired, tearful, or as if small electric pulses are moving through your head. An antidepressant change could be part of the reason. It could also be something else. Do not double your next dose. Do not build a rescue plan from this article. Check the instructions that came with your exact prescription, then call a pharmacist or the clinician who prescribes it.

Get urgent help now for a seizure, fainting, severe confusion, severe dehydration, new psychosis, signs of mania, or any medical emergency. If you may act on thoughts of suicide or cannot stay safe, call or text 988 in the United States. Call 911 or go to the nearest emergency department for immediate danger.

Key takeaways

• Antidepressant withdrawal is real, but no symptom or timeline proves that withdrawal is the cause.
• A safe taper is built around your medicine, history, response, supports, and symptoms. It is not one schedule copied from the internet.
• The decision about whether to stop is different from the plan for how to taper.

Zoom

Four different questions can feel the same

Withdrawal means symptoms that begin after a dose is reduced, doses are missed, or treatment is stopped. You may also hear “antidepressant discontinuation symptoms.” Both terms refer to the same clinical problem.

“Withdrawal” does not mean addiction. Physical dependence means the body has adapted to a medicine. It is a normal biological change, and it can happen with medicines that produce no high at all. Addiction involves a different pattern: craving, loss of control over use, and continued use despite harm.

Relapse means the treated depressive episode returns before recovery is well established. Recurrence means a new episode begins after a period of recovery. Side effects happen while taking a medicine and may change when the dose changes.

Low mood, anxiety, poor sleep, and irritability can occur in both withdrawal and depression. That is why a clinician looks at the full pattern instead of one symptom.

Withdrawal or relapse: clues, not a home test

The common shortcut says withdrawal starts in days and relapse takes weeks. That can help as a first clue, but it is not a rule. A medicine with a long half-life, meaning it leaves the body slowly, may produce delayed withdrawal. Relapse can happen early. Withdrawal can last longer than expected. A new illness can also begin at the same time.

What withdrawal can feel like

Reported symptoms include dizziness, unsteadiness, nausea, headache, sweating, chills, muscle aches, poor sleep, vivid dreams, fatigue, anxiety, irritability, crying, low mood, restlessness, and sensory changes. Some people describe brief electric-shock sensations as “brain zaps.” They are not required for the diagnosis.

The best current reviews answer different questions, and they do not all land in the same place.

A 2024 review pooled 79 studies and 21,002 participants. At least one symptom was reported by 31 percent of people who stopped an antidepressant. It was also reported by 17 percent of people who stopped placebo, a dummy pill with no active drug. In direct randomized comparisons, the placebo-adjusted difference was 8 percentage points. Severe symptoms were estimated in 2.8 percent after stopping a drug and 0.6 percent after stopping placebo, though those estimates were imprecise. The authors’ own bottom line is the most useful number here. Once the placebo effect is subtracted, they put the incidence at about 15 percent. That is roughly one in six to seven people who stop their medicine.1

A 2025 review looked only at randomized trials, covering 50 studies and 17,828 participants. It found about one extra withdrawal-scale symptom at one week. Dizziness and nausea showed the clearest placebo-adjusted differences. Dizziness affected about 6 percent more people than placebo. It did not find an increase in depressive symptoms during the first two weeks in the five trials that measured them. Those authors concluded that the average number of symptoms at one week fell below the threshold for a clinically significant discontinuation syndrome.2 That conclusion is debated. The review’s own authors note two limits that matter here: treatment in the included trials was probably shorter than real-world use, and some widely used medicines, including fluoxetine, were underrepresented.2 These trials say little about someone stopping after many years.

Patient guidance from the Royal College of Psychiatrists gives a higher figure. It estimates that a third to a half of people who take an antidepressant will get some withdrawal symptoms.3 These numbers are not in conflict. They count different things in different groups.

So there is no single “withdrawal rate.” Studies used different medicines, stopping methods, symptom lists, follow-up periods, and definitions. The studies do not erase severe or long-lasting experiences. They also do not show that everyone will have them.

Why one medicine may be harder to stop than another

Several factors can change risk:

• How quickly blood levels fall. Medicines with shorter half-lives can change faster after a missed dose. NICE advises prescribers to take the half-life into account, because a medicine that clears quickly may need a slower taper.4
• Active metabolites. Some medicines leave behind breakdown products that remain active in the body.
• The size of each pharmacologic change. A cut that looks small in milligrams may still be a meaningful change in effect.
• Dose, duration, and prior experience. A long treatment period, a previous difficult taper, or symptoms after missed doses may matter.
• Formulation. Available strengths and liquid forms affect how precisely a prescriber and pharmacist can plan reductions.
• The person. Sleep, stress, pregnancy, other medicines, alcohol or substances, health conditions, and individual sensitivity all matter.

In the 2024 review, desvenlafaxine, venlafaxine, imipramine, and escitalopram were linked with more symptoms in the available studies. Imipramine, paroxetine, and either desvenlafaxine or venlafaxine were linked with more severe symptoms; the review could not tell which of those last two carried the risk.1

Fluoxetine often changes more slowly, because it and an active metabolite remain in the body longer. Its manufacturer’s labeling notes that levels fall gradually after treatment ends, which may reduce the risk of discontinuation symptoms. That can lower risk for some people or simply delay onset. It does not make withdrawal impossible.

Why the last part may need smaller steps

A dose-response curve is not always a straight line. At higher doses, a few milligrams up or down may barely change the medicine’s target effect. The same few milligrams near the bottom of the range can change it a lot. In practice, the last few milligrams often carry more of the drug’s real effect than the first several.

Horowitz and Taylor examined brain imaging data on the serotonin transporter, the protein an SSRI blocks. The data showed how much of it is occupied at each dose. They found that cutting the dose in proportional, shrinking steps lowers the drug’s effect at that target in a steady, even way. They called this “hyperbolic” tapering. Guidelines had recommended short tapers of two to four weeks, down to the lowest marketed dose. Those short tapers showed little benefit over stopping abruptly, and were often not tolerated. Tapering over months, and down to doses well below the smallest tablet, showed better results in the studies they reviewed.5

This is a useful planning idea, not proof of one ideal schedule. Different antidepressants have different curves. Receptor models do not measure everything a person feels, and the approach has not been tested head-to-head against standard tapering in large trials. The safe principle is simpler. The smallest marketed tablet can still be a big final step. A prescriber may need more flexible tools and more time.

Tools a clinical team may consider

Depending on the exact product, the team may use a smaller manufactured strength, an approved liquid, pharmacist-supported measurement, or a properly prescribed compounded dose. NICE specifically suggests considering liquid preparations, where they exist, once doses get very small and tablets can no longer be divided finely enough.4 Availability and stability must be checked for the exact medicine and formulation.

Do not assume a tablet can be split, a capsule can be opened, beads can be counted, or an extended-release product can be crushed. Do not make a liquid at home. Those choices can change how a product releases, create uneven doses, or conflict with its label. A pharmacist can tell you what is safe for the product you actually have.

Skipping doses on alternate days is not a taper. For most medicines it makes drug levels swing up and down and can make withdrawal symptoms more likely.3

Switching to fluoxetine or returning to a prior dose appears in some clinical discussions. These are prescriber-led options, not do-it-yourself rescue methods. They can carry new risks and may be wrong for your diagnosis or your other medicines.

A milestone map instead of a fake calendar

A taper may take weeks for one person and months or longer for another. “Slow” is not a fixed number. A useful plan has milestones:

1. Before the first change: confirm why the medicine was prescribed, whether symptoms are in remission, and whether this is a stable time.
2. Choose a measurable first step: the prescriber specifies the exact product, dose, and timing. The pharmacist confirms how the formulation should be handled.
3. Observe: track physical symptoms, mood, sleep, function, and safety. Keep the rest of the plan steady when possible so the signal is easier to read.
4. Review before the next change: decide together whether to continue, hold, make a smaller next change, or reassess the diagnosis.
5. Plan the low-dose end: do not assume the final available tablet is a trivial step.
6. Continue follow-up after the last dose: time spent tapering and time spent having symptoms are not the same thing. Relapse risk also continues after the taper.

NICE advises reducing the dose in steps. Each step takes a proportion of the dose before it, and the reductions get smaller as the dose becomes lower. The next reduction should usually wait until withdrawal symptoms have resolved or are tolerable. The pace should be agreed with the person taking the medicine. NICE also notes that withdrawal may take weeks or months to complete.4 That is a decision process, not a percentage schedule for every reader.

The Royal College of Psychiatrists likewise stresses individual pacing. It notes that dose reductions usually get smaller as the dose drops. Someone who develops symptoms may need to go slower still, with smaller cuts spread over a longer time.3

A 2026 network meta-analysis pooled 76 trials and 17,379 participants. Slow tapering combined with psychological support lowered relapse compared with abrupt stopping, with a relative risk of 0.52, and worked about as well as staying on the medicine. Slow tapering on its own was not clearly better than abrupt stopping. The authors graded most of these comparisons as moderate to low certainty. Note what this review measured: relapse of the illness, not the severity of withdrawal symptoms.6

What a clinician may do if symptoms appear

The first job is reassessment. The clinician may review the timing, severity, safety, missed doses, formulation, other medicines, alcohol or substance use, sleep, and signs of a returning mood disorder or another medical condition. Depending on that assessment, the team may pause the taper, change its pace, use a different formulation, or treat another cause. They may also consider clinician-guided reinstatement. That means going back to a dose where you felt well, then trying again more slowly. None of these is automatic.

The ANTLER trial shows why the distinction can remain hard. It enrolled 478 adults in UK primary care who felt well enough to stop. Each had either two or more past depressive episodes, or two or more years on an antidepressant. All were taking citalopram, fluoxetine, sertraline, or mirtazapine. Relapse within 52 weeks occurred in 39 percent of those assigned to maintenance and 56 percent of those assigned to taper and placebo. Withdrawal symptoms were also more common after discontinuation, and the gap between groups was widest early, at about 12 weeks.7 A symptom score alone could not always cleanly separate withdrawal from relapse.

Your taper-planning checklist

Bring this list to the prescriber and pharmacist:

• diagnosis, number and severity of past episodes, and current remission status;
• exact medicine, manufacturer or product, dose, release type, and available strengths;
• total time taking it and any prior missed-dose or taper reactions;
• what withdrawal and relapse looked like before, if either occurred;
• current sleep, stress, work demands, caregiving, and major life changes;
• pregnancy, pregnancy planning, or postpartum status when relevant;
• all prescriptions, over-the-counter medicines, supplements, alcohol, and other substances;
• a person who can notice changes, with your permission;
• what you will track and when the clinician will review it;
• early warning signs and whom to contact after hours.

The separate question, “Is this the right time for me to stop?” belongs in a maintenance review, not in a taper template.

When to get help sooner

Contact the prescribing team promptly for severe or fast-worsening symptoms, inability to keep fluids down, major loss of function, or symptoms you cannot safely manage. Seek urgent assessment for suicidal thinking, inability to stay safe, mania or marked activation, psychosis, severe confusion, fainting, seizure, severe dehydration, or another medical emergency. Do not assume a dangerous symptom is “just withdrawal.”

What to do next

Write down the exact medicine, dose, formulation, last three doses, symptom start time, and your safest callback number. Then use the prescription instructions and contact a pharmacist or prescriber for the medication-specific next step.

Frequently asked questions

Can one missed antidepressant dose cause symptoms?

It can with some medicines and some people. Follow the product’s missed-dose instructions and ask a pharmacist or prescriber. Do not double a dose unless your clinician or label specifically directs it.

Are brain zaps dangerous?

Electric-shock sensations are reported in withdrawal, but they do not prove the cause. New neurologic symptoms, fainting, seizure, severe confusion, or unsafe distress need prompt assessment.

How long should an antidepressant taper take?

There is no universal duration. Some people taper over weeks, while others need months or longer. NICE notes that withdrawal may take weeks or months to complete, and the plan should be reviewed after each step.

How common is antidepressant withdrawal?

Estimates differ by study design. A 2024 meta-analysis put the incidence at about 15 percent, roughly one in six to seven people, after subtracting placebo effects. Patient guidance from the Royal College of Psychiatrists estimates a third to a half will have some symptoms.

Is withdrawal the same as addiction?

No. Physical dependence can occur without craving, loss of control, or compulsive use.

This article is for education, not personal medical advice. Do not start, stop, restart, or change a medication without the clinician who manages it. Every numeric, regulatory, and citation claim was verified against primary journal, federal, and labeling sources on September 7, 2026. Guidelines, drug labels, and public-health data change; confirm current status before acting on anything here.

Related reading on NP FADY

• Why antidepressants take time and how to use the first six weeks
• Antidepressant side effects and how clinicians manage them
• How Long Do I Have to Take This? What the Guidelines Actually Say About Antidepressant Duration

References

1. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. “Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.” The Lancet Psychiatry. 2024;11(7):526–535. DOI: 10.1016/S2215-0366(24)00133-0. PMID: 38851198. PubMed.

2. Kalfas M, Tsapekos D, Butler M, et al. “Incidence and nature of antidepressant discontinuation symptoms: a systematic review and meta-analysis.” JAMA Psychiatry. 2025;82(9):896–904. DOI: 10.1001/jamapsychiatry.2025.1362. PMID: 40632531. Full article.

3. Royal College of Psychiatrists. “Stopping antidepressants.” Current page checked September 7, 2026. Patient guidance.

4. National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). Published June 29, 2022; recommendations 1.4.12 to 1.4.17, current page checked September 7, 2026. Recommendations. See also Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215). Published April 20, 2022; recommendation 1.5.11. Recommendations.

5. Horowitz MA, Taylor D. “Tapering of SSRI treatment to mitigate withdrawal symptoms.” The Lancet Psychiatry. 2019;6(6):538–546. DOI: 10.1016/S2215-0366(19)30032-X. PMID: 30850328. PubMed.

6. Zaccoletti D, Mosconi C, Gastaldon C, et al. “Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis.” The Lancet Psychiatry. 2026;13(1):24–36. DOI: 10.1016/S2215-0366(25)00330-X. PMID: 41386898. Abstract.

7. Lewis G, Marston L, Duffy L, et al. “Maintenance or discontinuation of antidepressants in primary care.” New England Journal of Medicine. 2021;385(14):1257–1267. DOI: 10.1056/NEJMoa2106356. PMID: 34587384. PubMed.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.